Winton Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Winton Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,200	Closed	-$544K	–	701
2025 Q2	$544K	Buy	+25,200	New	+$468K	0.03%	576

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Winton Group's ACAD Position: Q3 2025 in Review

Winton Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 25,200 shares — an estimated $544K sold.

Winton Group first reported a position in ACAD in Q2 2025 and held it in 1 quarter. The position peaked at $544K in Q2 2025. 333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

Winton Group reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Winton Group sold 25,200 Acadia Pharmaceuticals shares in Q3 2025, an estimated $544K.
Winton Group first reported a position in Acadia Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Winton Group's Acadia Pharmaceuticals position peaked at $544K in Q2 2025.
333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.